Merck & Co. (MRK) : Rothschild Asset Management Inc scooped up 208,883 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 1,132,687 shares of Merck & Co. which is valued at $61 Million.Merck & Co. makes up approximately 1.16% of Rothschild Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Symphony Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 3,144 additional shares and now holds a total of 15,422 shares of Merck & Co. which is valued at $830,937. Merck & Co. makes up approx 0.16% of Symphony Asset Management’s portfolio.Tiaa Cref Investment Management reduced its stake in MRK by selling 1,125,365 shares or 8.47% in the most recent quarter. The Hedge Fund company now holds 12,164,896 shares of MRK which is valued at $652 Million. Merck & Co. makes up approx 0.49% of Tiaa Cref Investment Management’s portfolio.Argi Investment Services boosted its stake in MRK in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 28,578 shares of Merck & Co. which is valued at $1.5 Million. Merck & Co. makes up approx 0.16% of Argi Investment Services’s portfolio.Hirtle Callaghan Co boosted its stake in MRK in the latest quarter, The investment management firm added 8,385 additional shares and now holds a total of 8,969 shares of Merck & Co. which is valued at $480,738. Merck & Co. makes up approx 0.09% of Hirtle Callaghan Co’s portfolio.
Merck & Co. opened for trading at $55.81 and hit $56.67 on the upside on Wednesday, eventually ending the session at $56.57, with a gain of 1.74% or 0.97 points. The heightened volatility saw the trading volume jump to 96,01,393 shares. Company has a market cap of $156,587 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.